IP Library Granted Patent US 8,367,344
Granted Patent B2
US 8,367,344 · App. 12/761,649 · Granted Feb 5, 2013

Method of detecting oncogenesis of hematopoietic cells

Inventor: Gary Willard Reuther (Tampa, FL)
Assignee: University of South Florida
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,367,344
App. No.
12/761,649
Granted
Feb 5, 2013
Kind
B2
Abstract

Disclosed in a method of detecting cancer using IL-27 receptors. IL27R is a cytokine receptor identified as a novel oncogene from an acute myeloid leukemia patient. It induces cancer-like properties when expressed in cells and can activate a protein that causes various myeloid cell disorders. The data show cytokine receptors play unappreciated roles in mediating activation of signaling pathways in circulatory system cancers. Also method of screening for novel oncogenes using a functional, approach is disclosed using cytokine-dependent cells to screen for transforming events.

Claims (21)

1. A method of detecting leukemia, myeloproliferative diseases, myeloid tumors, and acute myeloid leukemia comprising the steps of:

providing a hematopoietic cell line or a sample comprising hematopoietic cells;

contacting the hematopoietic cell line or a sample comprising hematopoietic cells with an antibody which binds a biomarker for the cancerous disorders, wherein the biomarker is related to a component of interleukin 27 receptor;

allowing the biomarker to bind to the antibody; and

detecting the presence of the biomarker in said cell line or said sample using an immunoprotein assay;

wherein the presence of the biomarker is indicative of leukemia, myeloproliferative diseases, myeloid tumors, and acute myeloid leukemia.

2. The method of claim 1 , wherein the biomarker is selected from the group consisting of protein, peptide, or proteineaceous aggregate.

3. The method of claim 2 , wherein the biomarker is WSX-1.

4. The method of claim 1 , wherein the immunoprotein assay is selected from the group consisting of FACS, immunohistochemistry, and Western blot.

5. The method of claim 1 wherein the hematopoietic cell line or a sample comprising hematopoietic cells is mammalian.

6. The method of claim 5 wherein the hematopoietic cell line or a sample comprising hematopoietic cells is human.

7. A method of constructing a cancer research cell line, comprising the steps of

isolating RNA from cells obtained from a patient;

constructing cDNA from the RNA, wherein the cDNA encodes a heterodimeric transmembrane receptor protein for IL-27;

ligating the cDNA into a retroviral vector;

introducing the cDNA into a IL-27 dependent cell culture; and

removing an IL-27 cytokine from cell culture.

8. The method of claim 7 , wherein the gene introduced into the cell culture is a stably transfected into the cells.

9. The method of claim 7 , wherein the cDNA encodes WSX-1.

10. The method of claim 7 , wherein the cytokine dependent cells are selected from the group consisting of 32D and BaF3.

11. The method of claim 7 , further comprising introducing mutant JAK2V617F into the cells.

Assignments (2)
CONFIRMATORY LICENSE Recorded May 27, 2010
From: H. LEE MOFFITT CANCER CTR & RESEARCH INS
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024452/0262 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2010
From: REUTHER, GARY WILLARD
To: UNIVERSITY OF SOUTH FLORIDA
Reel/Frame 024425/0286 →
Continuity (3)
Continuation PCTUS2008080487 · Oct 20, 2008
Provisional Application 60980952 · Oct 18, 2007
Related Publication 20100196915A1 · Aug 5, 2010